What's new? Log in Free sign up

Disc Medicine (IRON)

Company Profile

Company profile

Ticker

IRON

Exchange

Website

geminitherapeutics.com

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology (except Nanobiotechnology)

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

FS Development Corp., Gemini Therapeutics, Inc. /DE

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Disc Medicine Opco, Inc. • Disc Medicine Securities Corp. • Gemini Therapeutics Sub, Inc.. ...

IRS number

851613057

IRON stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$91.75

Low target

$70.00

High target

$118.00

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Notice of effectiveness

Prospectus supplement for primary offering

Prospectus update (post-effective amendment)

Entry into a Material Definitive Agreement

Quarterly report

12 Nov 24

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP

Alignment with the FDA across all proposed study parameters, providing a clear development path to registration

Regulation FD Disclosure

Latest ownership filings

View all

Notice of proposed sale of securities

William Richard White

William Jacob Savage

Notice of proposed sale of securities

William Jacob Savage

Notice of proposed sale of securities

Bain Capital Life Sciences Opportunities III, LP

Paradigm Biocapital Advisors LP

BlackRock, Inc.

Financial summary

Financial statements Chart IRON financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	192.87 mm	192.87 mm	192.87 mm	192.87 mm		192.87 mm
Cash burn (monthly)	49.99 mm	15.40 mm	10.95 mm	9.42 mm		4.91 mm
Cash used (since last report)	139.55 mm	43.00 mm	30.57 mm	26.28 mm		13.69 mm
Cash remaining	53.32 mm	149.88 mm	162.30 mm	166.59 mm		179.18 mm
Runway (months of cash)	1.1	9.7	14.8	17.7		36.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

IRON institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	137	129	+6.2%
Opened positions	24	29	-17.2%
Closed positions	16	42	-61.9%
Increased positions	59	56	+5.4%
Reduced positions	27	30	-10.0%

13F shares	Current	Prev Q	Change
Total value	1.28 tn	1.19 tn	+7.7%
Total shares	40.27 mm	40.69 mm	-1.0%
Total puts	7.30 k	11.40 k	-36.0%
Total calls	7.40 k	33.10 k	-77.6%
Total put/call ratio	1.0	0.3	+186.4%

Largest owners	Shares	Value	Change
Ai Dmi	3.76 mm	$168.79 mm	0.0%
Access Industries Management	3.35 mm	$165.35 mm	0.0%
Atlas Venture Life Science Advisors	2.51 mm	$123.31 bn	0.0%
BLK BlackRock	1.85 mm	$90.97 bn	NEW
Wellington Management	1.84 mm	$90.43 bn	+4.8%
Bain Capital Life Sciences Investors	1.80 mm	$88.24 bn	0.0%
Bain Capital Life Sciences Opportunities III	1.80 mm	$81.89 mm	-9.8%
Orbimed Advisors	1.79 mm	$87.74 bn	0.0%
Frazier Life Sciences Management	1.75 mm	$86.23 bn	0.0%
Atlas Venture Fund X	1.59 mm	$86.30 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	1.85 mm	+1.85 mm	NEW
BLK BlackRock	0.00	-1.44 mm	EXIT
Paradigm Biocapital Advisors	1.50 mm	-1.21 mm	-44.6%
JHG Janus Henderson	749.83 k	+303.95 k	+68.2%
Polar Capital	0.00	-244.93 k	EXIT
STT State Street	827.91 k	+235.12 k	+39.7%
Bain Capital Life Sciences Opportunities III	1.80 mm	-195.18 k	-9.8%
Perceptive Advisors	387.02 k	-166.42 k	-30.1%
Armistice Capital	160.00 k	+160.00 k	NEW
First Turn Management	0.00	-138.91 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IRON insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 24	John D Quisel	Common Stock	Sell	Dispose S	No	Yes	67.198	500	33.60 k	72,065
16 Dec 24	John D Quisel	Common Stock	Sell	Dispose S	No	Yes	66.3539	6,305	418.36 k	72,565
16 Dec 24	John D Quisel	Common Stock	Sell	Dispose S	No	Yes	65.5789	5,767	378.19 k	78,870
16 Dec 24	John D Quisel	Common Stock	Sell	Dispose S	No	Yes	64.6586	219	14.16 k	84,637
16 Dec 24	John D Quisel	Common Stock	Option exercise	Acquire M	No	Yes	1.01	12,791	12.92 k	84,856
16 Dec 24	John D Quisel	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	1.01	12,791	12.92 k	225,420
2 Dec 24	William Richard White	Common Stock	Sell	Dispose S	No	Yes	65.3343	173	11.30 k	0
2 Dec 24	William Richard White	Common Stock	Sell	Dispose S	No	Yes	64.58	1,762	113.79 k	173
2 Dec 24	William Richard White	Common Stock	Sell	Dispose S	No	Yes	63.4941	22	1.40 k	1,935
2 Dec 24	William Richard White	Common Stock	Option exercise	Acquire M	No	Yes	9.86	201	1.98 k	1,957

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Stifel Maintains Buy on Disc Medicine, Raises Price Target to $90

Stifel analyst Benjamin Burnett maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $79 to $90.

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $118 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $118 price target.

Reported Sunday, Disc Medicine Shares Phase 1b Results For DISC-0974 In Myelofibrosis Patients At ASH 2024, Starts Phase 2 Trial

Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated, enrolling a broad

HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $118

Disc Medicine Q3 EPS $(0.89) Beats $(1.05) Estimate

Press releases

From Benzinga Pro

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement hosted a conference

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated, enrolling a broad

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc's sole discretion through second-half

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.